- Global Pharma News & Resources

Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the second consecutive year. Cidara ranked among the top 15 small companies, and the number one ranked biotech in the small company category, in the San Diego Metro Area.

“We are once again honored to be recognized as a top workplace by our employees, whose feedback reflects our commitment to nurturing a positive work environment where we are true to our values and advocate for integrity, collaboration, urgency, accountability and courage,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We foster innovation by challenging the status quo, encouraging new ideas and enabling autonomy, all while working with conviction at a pace that reflects the needs of the patients we serve.”

Top Workplace lists are based solely on employee feedback gathered through a third-party survey administered by Energage, LLC, a leading provider of technology-based employee engagement tools. The anonymous survey measures several aspects of workplace culture, including alignment, execution, and connection. According to Energage, 100 percent of Cidara employees participated in the 2018 survey.

From its inception, Cidara leadership identified the core principles that would drive the company’s culture. From there, the entire organization fleshed out these principles to make that vision a reality, and to identify and articulate the common behaviors under each of these principles for which they would be accountable. The company continues to build and sustain this strong, principle-based culture as they work to bring lifesaving anti-infectives to patients.

The San Diego Union-Tribune published the complete list of 2018 Top Workplaces on Sunday, November 11. The list of winners is available at:

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial in the treatment of candidemia and invasive candidiasis and plans to initiate a second Phase 3 trial in the prophylaxis of invasive fungal infections. Rezafungin has improved pharmacokinetics compared to existing echinocandins and the potential for expanded utility across patient settings. It is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. Cidara also is leveraging its novel Cloudbreak™ platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California. For more information, please visit

View source version on

Editor Details

Last Updated: 12-Nov-2018